UNC researcher develops innovative drug to treat Sickle Cell patients
Posted Dec 9, 2016
A new drug shows dramatic promise to help Sickle Cell patients reduce painful episodes. UNC's Dr. Kenneth Ataga was the principal investigator for an investigational drug called Crizanlizumab. The trial involved 198 participants in a multi-center, randomized trial. The “Sustain Trial” results were published online by the New England Journal of Medicine.
(WRAL.com)
Related: Campus Connections
UNC Disc Golf Team Wins National ChampionshipCarolina Disc Golf is a club team dedicated to growing the game of disc golf. UNC traveled to Rock Hill, South Carolina last weekend to...
Wed Apr 24, 2024Multiple UNC Graduate School Programs Ranked in Nation’s Top 10
Several University of North Carolina graduate programs were ranked in the top 10 of their respective categories by the U.S. News & World Report this...
Sun Apr 21, 2024
Classey, Van Ord run away with Tar Heel 10 Miler victories
Former Wofford cross country runner Beck Classey of Greenville and accomplished marathoner Tristin Van Ord coasted to victories Saturday at the Tar Heel 10 Miler...
Sat Apr 20, 2024
UNC Alumna at Nike endows Carolina Covenant scholarship
Ilana Finley ’00 is creating her own Tar Heel legacy by endowing a scholarship through the Carolina Covenant. After graduating with a bachelor’s degree in...
Fri Apr 19, 2024